MUC1 and ovarian carcinoma: Subsequently, the in vitro behavior of DFO-AR20.5 was evaluated via flow cytometry experiments with MUC1-expressing SKOV3 human ovarian cancer cells, ultimately confirming the ability of the immunoconjugate to bind its molecular target (Supplementary Figure S3).